We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
On track to initiate a Phase 3 program for Companyโs lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia...
ย Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (โAmylyxโ or the โCompanyโ) will report its third quarter 2024 financial results on Thursday, November 7, 2024. Amylyxโ senior management team will...
- Improvement observed in pancreatic function, as measured by C-peptide response, following 24 weeks of treatment with AMX0035; worsening is typically expected with disease progression based on...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (โAmylyxโ or the โCompanyโ) today announced the Company will host a virtual webcast on October 17, 2024 at 1:30 p.m. ET with management and Fumihiko...
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Oct. 3, 2024 NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.31 | -5.70902394107 | 5.43 | 5.88 | 4.57005 | 1995624 | 5.11759761 | CS |
4 | 0.12 | 2.4 | 5 | 7.27 | 4.57005 | 1626616 | 5.63435348 | CS |
12 | 3.02 | 143.80952381 | 2.1 | 7.27 | 2.08 | 1473597 | 4.25791851 | CS |
26 | 3.28 | 178.260869565 | 1.84 | 7.27 | 1.575 | 1540362 | 2.95918779 | CS |
52 | -7.77 | -60.2792862684 | 12.89 | 19.9488 | 1.575 | 1916483 | 5.30794866 | CS |
156 | -15.88 | -75.619047619 | 21 | 41.9297 | 1.575 | 1362339 | 14.84053433 | CS |
260 | -15.88 | -75.619047619 | 21 | 41.9297 | 1.575 | 1362339 | 14.84053433 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions